Quick Answer
Cytek Biosciences, Inc. reported Research And Development Expense of $36.47 million for the year ending 2025.
- Cytek Biosciences, Inc. showed a decrease of -7.4% in Research And Development Expense from 2024 to 2025.
- This data is from Cytek Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $2.92 million | Q3 2020: $3.38 million | Q1 2021: $5.09 million | Q2 2021: $6.19 million | Q3 2021: $6.08 million | Q1 2022: $8.03 million | Q2 2022: $8.44 million | Q3 2022: $8.65 million | Q1 2023: $9.97 million | Q2 2023: $12.14 million | Q3 2023: $11.17 million | Q1 2024: $9.80 million | Q2 2024: $10.00 million | Q3 2024: $9.88 million | Q1 2025: $9.73 million | Q2 2025: $8.83 million | Q3 2025: $8.96 million.
- Over the full 6 years of available data (2020 to 2025), Cytek Biosciences, Inc.'s Research And Development Expense has grown by 166.3%.
- Historical annual values: Fiscal year 2025: $36.47 million | Fiscal year 2024: $39.40 million | Fiscal year 2023: $44.15 million | Fiscal year 2022: $34.86 million | Fiscal year 2021: $24.44 million | Fiscal year 2020: $13.69 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: